Related Experiment Video

Updated: Aug 6, 2026

Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis
06:56

Antibody Transfection into Neurons as a Tool to Study Disease Pathogenesis

Published on: September 26, 2012

Ulip/CRMP proteins are recognized by autoantibodies in paraneoplastic neurological syndromes

J Honnorat1, T Byk, I Kusters

  • 1INSERM U 433, Hôpital Neurologique, Lyon, France. honnorat@cismsun.univ-lyon1.fr

The European Journal of Neuroscience
|December 14, 1999
PubMed

Insights

Autoantibodies targeting CV2 (collapsin response mediator protein 2) are linked to paraneoplastic neurological diseases (PND). These antibodies recognize Ulip4/CRMP3, a protein crucial for oligodendrocyte function and potentially implicated in PND.

Area of Science:

  • Neuroimmunology
  • Molecular Neuroscience
  • Oncology

Background:

  • Paraneoplastic neurological diseases (PND) involve autoimmune processes causing neuronal degeneration in cancer patients.
  • Anti-CV2 autoantibodies have been recently identified in PND patients.
  • These autoantibodies target a 66 kDa brain protein expressed in adult brain oligodendrocytes.

Purpose of the Study:

  • To identify the specific target recognized by anti-CV2 autoantibodies.
  • To investigate the role of the target protein in PND pathophysiology.
  • To determine the genetic location and characteristics of the target protein.

Main Methods:

  • Immunological assays using patient sera.
  • Protein characterization and identification.
  • Gene sequencing and chromosomal localization.

Main Results:

  • Anti-CV2 sera recognize post-translationally modified forms of Ulip4/CRMP3 (collapsin response mediator protein 3).
  • Ulip4/CRMP3 is a member of a protein family involved in axonal guidance.
  • The human Ulip4/CRMP3 gene is located on chromosome 10q25.2-q26.

Conclusions:

  • Ulip4/CRMP3 is the antigen targeted by anti-CV2 autoantibodies in PND.
  • Understanding Ulip4/CRMP3's role in oligodendrocytes may elucidate PND mechanisms.
  • The genetic localization suggests potential links to tumor suppressor genes and glioblastomas.

More Related Videos

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

Related Concept Videos

Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...